Trubion Pharmaceuticals Inc. Provides Announcement Dates for Second Quarter and First Six Months Earnings Conference Call
SEATTLE, July 31 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals Inc. today announced that it plans to issue earnings results for second quarter and first six months ended June 30, 2008, after the close of market on Aug. 7, 2008. The company's earnings conference call will take place Aug. 7, 2008, at 2 p.m. PDT (5 p.m. EDT).
Both live events will be available for viewing on Trubion's website at http://investors.trubion.com/events.cfm.
Second Quarter and First Six Months Earnings Conference Call: 2 p.m. PDT / 5 p.m. EDT, Aug. 7, 2008
Trubion will host a conference call and webcast to discuss its second quarter and six months 2008 financial results. The call will be held Aug. 7 at 2 p.m. Pacific time (5 p.m. Eastern time). The live event will be available from Trubion's website at http://investors.trubion.com/events.cfm, or by calling 1 (719) 325-4916 or 1 (877) 397-0292. A replay of the discussion will be available from Trubion's website or by calling 1 (719) 457-0820 or 1 (888) 203-1112 and entering 6969493. Replay will be available at 8 p.m. EDT until midnight, Aug. 14, 2008. The webcast replay will be available in the events section of Trubion's website.
About Trubion
Trubion is a biopharmaceutical company that is creating a pipeline of novel protein therapeutic product candidates to treat autoimmune and inflammatory diseases and cancer. The company's mission is to develop a variety of first-in-class and best-in-class product candidates, customized for optimal safety, efficacy, and convenience that it believes may offer improved patient experiences. Trubion's current product candidates are novel single-chain protein, or SMIP(TM), therapeutics, and are designed using its custom drug assembly technology. Trubion's product pipeline includes CD20-directed candidates such as TRU-015 and SBI-087 for autoimmune and inflammatory diseases, developed under the company's Wyeth collaboration. Trubion's product pipeline also includes Trubion's proprietary product candidate, TRU-016, a novel CD37-targeted therapy for the treatment of B-cell malignancies that is currently in Phase 1/2 clinical evaluation. In addition to Trubion's current product candidates, the company is also developing additional alliance and proprietary product candidates that build on its product development experience. More information is available in the investors section of Trubion's website: investors.trubion.com.
TRBN-G
CONTACT: Jim DeNike, Senior Director, Corporate Communications of Trubion
Pharmaceuticals Inc., +1-206-838-0500, jdenike@trubion.com; or Amy Petty,
Senior Account Executive, Waggener Edstrom Worldwide Healthcare,
+1-617-576-5788, amyp@waggeneredstrom.com, for Trubion Pharmaceuticals Inc.
Web site: http://www.trubion.com/